You searched for tim brennan

Eyes Wide Open Episode 1: Finding Stars – Avoiding Passengers

Monday, September 23 2019 | 13 h 44 min | News, Podcast

In the new podcast Eyes Wide Open, host Dr Glen Chiasson casts a curious eye on topics of relevance and interest to Canadian Eye Care professionals...

Image representing eye-care recruitment: lose-up photograph of a row of "meeple" game pieces; a hand has selected one piece and a smiley face is super-imosed over that piece.

Seeing Beyond the Crisis: A Strategic Vision for Eye Care Recruitment

Tuesday, April 16 2024 | 08 h 30 min | Practice Management

By Tim Brennan The eye care industry, a nexus of health, style, and innovation, is at a critical juncture Despite being a field ripe with...

Making Informed Decisions About your Professional Career

Monday, October 18 2021 | 08 h 27 min | Events, News, Press Release

The employment market in eye care has always been a challenge but today, catalyzed by the new opportunities from eyecare organizations and...

Recruiting and Team Building in 2021 and Beyond. Get Ready Now.

Wednesday, October 13 2021 | 09 h 35 min | News

Way back in 2019 we were feeling the challenges of recruiting and the last two years have added a whole new wrinkle Since March of 2020, we have...

Eyeployment.com Offers Free Career Planning Tool to Optical Industry

Thursday, April 9 2020 | 09 h 24 min | Announcements, EyeCareBusiness.ca, Latest News, News

Eyeploymentcom, the eye care and eyewear Industry’s advanced candidate assessment technology platform, is making a career planning tool available...

1 2 Next »

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Search Results for: tim brennan

Eyes Wide Open Episode 1: Finding Stars – Avoiding Passengers

Seeing Beyond the Crisis: A Strategic Vision for Eye Care Recruitment

Making Informed Decisions About your Professional Career

Recruiting and Team Building in 2021 and Beyond. Get Ready Now.

Eyeployment.com Offers Free Career Planning Tool to Optical Industry

Featured Posts

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement